A Day Of Reckoning for Aging Facilities: Is It Time To Invest In Change?
This article was originally published in Scrip
With its acquisition of Hospira, Pfizer joins those struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades. Meanwhile, flexible, modular next-generation facilities are looming. Bowman Cox, editor of "The Gold Sheet" looks at the possibilities for the industry's golden oldies.
Register for our free email digests: